Hemispherx Biopharma, Inc. announced appointment of Joseph Horvath as deputy chief medical officer, to oversee Ampligen European pancreatic cancer programs. In this newly-created position, Dr. Horvath will assist the Company on various scientific aspects of development, manufacturing, regulatory, and medical affairs with a focus on assisting with the oversight of the current Ampligen Early Access Program (EAP) in place for pancreatic cancer. He served as Hemispherx' Director of R&D for seven years. He also served as Scientific Director of the Biotherapy Research Laboratories at St. Joseph Hospital's Cancer Institute in Tampa, FL.